This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gustafsson, I.
Right arrow Articles by Cars, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gustafsson, I.
Right arrow Articles by Cars, O.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2000, p. 1846-1849, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro Pharmacodynamics of the New Ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae

I. Gustafsson,1,* E. Hjelm,2 and O. Cars1

Departments of Infectious Diseases1 and Clinical Microbiology,2 University Hospital, Uppsala, Sweden

Received 24 November 1999/Returned for modification 8 February 2000/Accepted 29 March 2000

The ketolides HMR 3004 and HMR 3647 (telithromycin) are a new class of macrolides that have a potential clinical efficacy against intracellular pathogens. The objectives of this study were to investigate the MIC, minimum bactericidal concentration, and time-dependent killing of two Chlamydia pneumoniae strains of the two ketolides. The killing effect was also studied with a newly developed intracellular in vitro kinetic model. Furthermore, HMR 3647 was studied for the effect of a subinhibitory concentration of 0.5 times the MIC after a preexposure of 10 times the MIC during 12 h. The MICs for both strains were 0.0039 and 0.0156 mg/liter for HMR 3004 and HMR 3647, respectively. Killing with 10 times the MIC was time dependent, increasing from a 1-log-unit decrease in the number of inclusions per well at 48 h to a maximal effect of 2.8-log-unit decrease after 96 h. A preexposure of 10 times the MIC of HMR 3647 for 12 h followed by a subinhibitory concentration of 0.5 times the MIC increased the killing effect to a 1.2-log-unit reduction in inclusions per well. An exposure for 12 h gave poor reduction of inclusions, while a static dose of 10 times the MIC for 72 h showed a 2.2-log-unit reduction in inclusions per well. In the kinetic model, a small number of inclusions were detected after 72 h by one exposure of 10 times the MIC. Regrowth could not be detected after 120 h. The ketolides HMR 3004 and HMR 3647 have bactericidal activity and show a significant sub-MIC effect on the intracellular pathogen C. pneumoniae.


* Corresponding author. Mailing address: Department of Clinical Microbiology, University Hospital, SE-751 85 Uppsala, Sweden. Phone: 46 (18) 66 39 10. Fax: 46 (18) 55 91 57. E-mail: ingegerd.gustafsson{at}medsci.uu.se.


Antimicrobial Agents and Chemotherapy, July 2000, p. 1846-1849, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Lippert, C., Gbenado, S., Qiu, C., Lavin, B., Kovacs, S. J. (2005). The Bioequivalence of Telithromycin Administered Orally as Crushed Tablets Versus Tablets Swallowed Whole. J Clin Pharmacol 45: 1025-1031 [Abstract] [Full Text]  
  • Ackermann, G., Rodloff, A. C. (2003). Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide. J Antimicrob Chemother 51: 497-511 [Abstract] [Full Text]  
  • Miyashita, N., Fukano, H., Niki, Y., Matsushima, T. (2001). In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 48: 403-405 [Abstract] [Full Text]